D. J. Deangelo

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias

D. J. Deangelo, Richard M. Stone, L. B. Silverman et al. · Journal of Clinical Oncology · 2006 · 226 citations

Gamma Secretase, Immunology, Pharmacotherapy +18

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction

Catia Fonseca, Robert J. Soiffer, Vincent T. Ho et al. · Blood · 2008 · 36 citations · Full text

Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies

Eric K. Rowinsky, Johann S. de Bono, D. J. Deangelo et al. · Journal of Clinical Oncology · 2005 · 31 citations

Cardiovascular Pharmacology, Pathology, Pharmacotherapy +25

A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies

Oliver G. Ottmann, D. J. Deangelo, R. M. Stone et al. · Journal of Clinical Oncology · 2004 · 14 citations

Immunology, Pharmacotherapy, Hdac Activity +20

S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM)

Deepti Radia, M. Deininger, Jason Gotlib et al. · HemaSphere · 2019 · 10 citations · Full text